Both HO-1 and Cyp3A11 are not directly associated with any current SCD clinical trials, and our results also highlight the potential novel therapeutic avenues of these two compounds in non-steroidal analgesic-driven end-organ damage, as well as hemolytic complications associated with SCD. Here, HMOX1 is linked to Schnyder corneal dystrophy.